Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Postgrad Med. 2004 Feb;115(2):15-8, 21, 24-6.

Initiating HIV therapy. Timing is critical, controversial.

Author information

  • University of California, San Francisco, School of Medicine, UCSF-Gladstone Institute of Virology and Immunology Center for AIDS Research, San Francisco Veterans Affairs Medical Center, USA. paul.volberding@med.va.gov

Abstract

Currently available antiretroviral drug regimens are able to suppress HIV replication and allow CD4 recovery in the vast majority of patients with HIV infection. The challenge is to match each patient to the regimen that is most likely to durably suppress HIV replication enough to prevent resistance selection without causing treatment-limiting toxicities. It is also critical, but difficult, to know when to begin treatment relative to CD4 cell count and plasma viral load. In this article, Dr Volberding addresses the central questions surrounding antiretroviral treatment initiation and reviews some available treatment options.

PMID:
15000057
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk